Table 2.
Subgroup analysis of the prevalence of macroprolactinemia among patients with hyperprolactinemia.
| Study Characteristic | Number of Studies | Random Effect Pooled Prevalence | 95% CI of Pooled Prevalence | Within Group Heterogeneity | Between Group Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|
| I2 (%) | χ2 (df) | p-Value | χ2 (df) | p-Value | ||||
| Region | ||||||||
| European Region | 37 | 17.5 | 14.0, 21.2 | 95.7 | 840.70 (36) | <0.001 | 7.32 (3) | 0.062 |
| Region of the Americas | 14 | 29.1 | 18.5, 41.0 | 97.1 | 455.07 (13) | <0.001 | ||
| Western Pacific Region | 7 | 12.6 | 6.7, 19.9 | 89.3 | 55.94 (6) | <0.001 | ||
| South-East Asian Region | 3 | 12.7 | 4.7, 23.1 | - | - | - | ||
| African Region | 2 | 30.3 | 25.0, 36.0 | - | - | - | ||
| Eastern Mediterranean Region | 4 | 13.9 | 4.8, 26.3 | 83.8 | 18.53 (3) | <0.001 | ||
| Sex | ||||||||
| Both (male and female) | 52 | 17.1 | 13.8, 20.6 | 96.2 | 1359.49 (51) | <0.001 | 6.56 (1) | 0.010 |
| Female only | 14 | 25.4 | 19.6, 31.6 | 84.9 | 86.49 (13) | <0.001 | ||
| Male only | 1 | 41.2 | 24.6, 59.3 | - | - | - | ||
| Age group | ||||||||
| Adults only | 48 | 19.8 | 16.6, 23.2 | 93.3 | 697.08 (47) | <0.001 | 0.23 (1) | 0.630 |
| Teenagers and adults | 10 | 18.0 | 11.9, 25.0 | 92.2 | 114.91 (9) | <0.001 | ||
| Teenagers only | 1 | 21.9 | 9.3, 40.0 | - | - | - | ||
| Year period | ||||||||
| Before 2000 | 4 | 26.5 | 11.2, 45.2 | 95.4 | 64.56 (3) | <0.001 | 2.64 (2) | 0.267 |
| Between 2000 and 2009 | 30 | 20.4 | 16.5, 24.5 | 94.6 | 536.29 (29) | <0.001 | ||
| Between 2010 and 2019 | 33 | 16.4 | 12.4, 20.9 | 94.3 | 557.34 (32) | <0.001 | ||
| PEG type | ||||||||
| PEG 6000 | 47 | 18.8 | 15.0, 23.0 | 95.6 | 1053.67 (46) | <0.001 | 0.06 (1) | 0.801 |
| PEG 8000 | 6 | 16.7 | 7.8, 27.7 | 90.6 | 53.43 (6) | <0.001 | ||
PEG: Polyethylene glycol.